<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816697</url>
  </required_header>
  <id_info>
    <org_study_id>16-208</org_study_id>
    <nct_id>NCT02816697</nct_id>
  </id_info>
  <brief_title>Implementation of a System-level Tobacco Treatment Intervention</brief_title>
  <official_title>Implementation of a System-level Tobacco Treatment Intervention in Thoracic Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study plans to adapt and study the implementation and effectiveness of&#xD;
      integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the&#xD;
      thoracic oncology setting using mixed methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In particular the study aims to see if participants are asked about their smoking status and&#xD;
      what services are offered if someone indicates being a former or current smoker. Findings&#xD;
      from this study will help improve a standard of care at this clinic and allow us to&#xD;
      understand what type of tobacco treatment services are preferred by patients.&#xD;
&#xD;
        -  Adaption of CEASE will entail exit interviews with patients and individual interviews&#xD;
           with clinical staff to identify and address facilitators and barriers to the&#xD;
           implementation process.&#xD;
&#xD;
        -  Effectiveness of CEASE will be measured through questionnaires &amp; biochemical&#xD;
           verification of smoking status using a pre-test/post-test study design before (usual&#xD;
           care)and after implementation (CEASE)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking cessation Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>Biochemical verification of smoking cessation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documentation of tobacco treatment</measure>
    <time_frame>2 months after CEASE</time_frame>
    <description>Assess documentation of smoking assessment and provision of treatment ( medication and referral for behavioral counseling)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cease-Aim 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cease Implementation&#xD;
100 Patients after CEASE Implementation&#xD;
Exit Interview and Tobacco Use Survey</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre Cease Implementation Aim 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)&#xD;
Tobacco Use Survey (Baseline,1- 6 Months)&#xD;
Biochemical verification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After Cease Implementation Aim 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 Current or former smokers (3 months +/-2 month)&#xD;
Tobacco Use Survey (Baseline,1- 6 Months)&#xD;
Biochemical verification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care-Aim 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual Care Tobacco Treatment Services&#xD;
100 patients in usual care&#xD;
Exit Interview and Tobacco Use Survey</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinician and Staff Survey</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>- Interview clinicians and support staff (40)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CEASE</intervention_name>
    <description>Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)&#xD;
CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits</description>
    <arm_group_label>After Cease Implementation Aim 2</arm_group_label>
    <arm_group_label>Cease-Aim 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care Tobacco Treatment Services</intervention_name>
    <arm_group_label>Pre Cease Implementation Aim 2</arm_group_label>
    <arm_group_label>Usual Care-Aim 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Have an actual or potential diagnosis of thoracic malignancy&#xD;
&#xD;
          -  Able to read and write in English.&#xD;
&#xD;
          -  Current or recent former smoker (defined as having smoked within past 6 months)&#xD;
&#xD;
          -  Must have an active telephone number.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Former smoker greater than 6 months.&#xD;
&#xD;
          -  Have any of the below conditions needing immediate medical intervention&#xD;
&#xD;
               -  Hypercalcemia causing lethargy and confusion,&#xD;
&#xD;
               -  Acute respiratory distress&#xD;
&#xD;
               -  Dehydration&#xD;
&#xD;
               -  Hypotension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary E Cooley, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Mary E. Cooley, Phd</investigator_full_name>
    <investigator_title>Mary E. Cooley MD</investigator_title>
  </responsible_party>
  <keyword>Smoking Habits</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

